Though oligonucleotide probe arrays are not yet on the drug store counter top nor even in the doctor's office, we are not in the genetic Kansas anymore. The pace of genetic technologies is quickening, and we have not yet figured out how to handle the implications of the clinical genetics we already have available to us. Will we be able to use this technology for the good of all concerned? Or will the imperative "a technological can do implies a commercial must do," rule this new technology as it seems to rule so many others? Let us examine some of the benefits and risks of this new technology.

Was this article helpful?

0 0

Post a comment